BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jang JW, Park YM, Bae SH, Choi JY, Yoon SK, Chang UI, Nam SW, Kim BS. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol. 2004;54:415-420. [PMID: 15235823 DOI: 10.1007/s00280-004-0829-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Hara E, Makino A, Kurihara K, Ueda M, Hara I, Kawabe T, Yamamoto F, Ozeki E, Togashi K, Kimura S. Radionuclide therapy using nanoparticle of 131I-Lactosome in combination with percutaneous ethanol injection therapy. J Nanopart Res 2013;15. [DOI: 10.1007/s11051-013-2131-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
2 Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
3 Kim JS, Park YM, Kim NY, Yun HK, Lee KJ, Kim BH, Park SJ, Yeon JW, Jung G. Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results. Korean J Hepatol 2011;17:120-9. [PMID: 21757983 DOI: 10.3350/kjhep.2011.17.2.120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, Cho SH, Han JY, Lee YS. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43:233-240. [PMID: 16440357 DOI: 10.1002/hep.21024] [Cited by in Crossref: 138] [Cited by in F6Publishing: 134] [Article Influence: 8.6] [Reference Citation Analysis]
5 Wang S, Xie X, Wong CST, Choi PY, Fung MC. HepG2 cells recovered from apoptosis show altered drug responses and invasiveness. Hepatobiliary & Pancreatic Diseases International 2014;13:293-300. [DOI: 10.1016/s1499-3872(14)60042-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
6 Woo HY, Jang JW, Choi JY, Bae SH, You CR, Rha SE, Lee YJ, Yoon SK, Lee CD. Tumor doubling time after initial response to transarterial chemoembolization in patients with hepatocellular carcinoma. Scand J Gastroenterol. 2010;45:332-339. [PMID: 20001605 DOI: 10.3109/00365520903456573] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
7 Lee SW, Lee HL, Han NI, Kwon JH, Nam SW, Jang JW, Bae SH, Choi JY, Yoon SK. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. Ther Adv Med Oncol 2017;9:615-26. [PMID: 28974984 DOI: 10.1177/1758834017728018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Jang JW, Choi JY, Bae SH, Kim CW, Cho SH, Yoon SK, Yang JM, Han JY, Lee YS, Kim DG. The best candidates for transarterial chemotherapy in patients with hepatocellular carcinoma awaiting liver transplantation: a cohort-based characterization of dropout times: BEST CANDIDATES FOR PRE-TRANSPLANT TRANSARTERIAL THERAPY IN HCC. Alimentary Pharmacology & Therapeutics 2007;26:87-94. [DOI: 10.1111/j.1365-2036.2007.03345.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
9 Jang JW, Choi JY, Bae SH, Yoon SK, Woo HY, Chang UI, Kim CW, Nam SW, Cho SH, Yang JM. The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence. Cancer. 2007;110:1760-1767. [PMID: 17724708 DOI: 10.1002/cncr.22984] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
10 Jung SM, Jang JW, You CR, Yoo SH, Kwon JH, Bae SH, Choi JY, Yoon SK, Chung KW, Kay CS, Jung HS. Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases. J Gastroenterol Hepatol. 2012;27:684-689. [PMID: 21916984 DOI: 10.1111/j.1440-1746.2011.06917.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
11 Woo HY, Youn JM, Bae SH, Jang JW, Cha JH, Kim HL, Chun HJ, Choi BG, Choi JY, Yoon SK. Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis. Korean J Hepatol 2012;18:32-40. [PMID: 22511901 DOI: 10.3350/kjhep.2012.18.1.32] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
12 Kim YW, Kwon JH, Nam SW, Jang JW, Jung HS, Shin YR, Park ES, Shim DJ. Sustained multiple organ ischaemia after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. Exp Ther Med 2018;15:1479-83. [PMID: 29434732 DOI: 10.3892/etm.2017.5540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
13 Lee CY, Bae MK, Park IK, Kim DJ, Lee JG, Choi JS, Han KH, Chung KY. Surgical resection for pulmonary metastasis from hepatocellular carcinoma: analysis of prognosis in relation to primary control. J Surg Oncol. 2010;101:239-243. [PMID: 20127898 DOI: 10.1002/jso.21487] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
14 Asmane I, Litique V, Heymann S, Marcellin L, Métivier AC, Duclos B, Bergerat JP, Kurtz JE. Adriamycin, cisplatin, ifosfamide and paclitaxel combination as front-line chemotherapy for locally advanced and metastatic angiosarcoma. Analysis of three case reports and review of the literature. Anticancer Res 2008;28:3041-5. [PMID: 19031953 [PMID: 19031953 DOI: 10.1097/cad.0b013e32830c2380] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
15 Kwon JB, Park K, Kim YD, Seo JH, Moon SW, Cho DG, Kim YW, Kim DG, Yoon SK, Lim HW. Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma: Analysis of prognostic factors. World J Gastroenterol 2008; 14(37): 5717-5722 [PMID: 18837090 DOI: 10.3748/wjg.14.5717] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
16 Wang ZX, Liu SL, Sun CH, Wang Q. Psychological intervention reduces postembolization pain during hepatic arterial chemoembolization therapy: A complementary approach to drug analgesia. World J Gastroenterol 2008; 14(6): 931-935 [PMID: 18240352 DOI: 10.3748/wjg.14.931] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
17 Peng BG, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg. 2009;198:313-318. [PMID: 19285298 DOI: 10.1016/j.amjsurg.2008.09.026] [Cited by in Crossref: 87] [Cited by in F6Publishing: 96] [Article Influence: 6.7] [Reference Citation Analysis]
18 Oh YJ, Park YM, Kim BH, Kim MJ, Cho JH, Cha CW, Park SJ, Yeon JW. A case of hepatocellular carcinoma with pulmonary metastases treated successfully with a combination of repeated hepatic arterial infusion epirubicin and Cisplatin chemotherapy and systemic low-dose infusion of 5-Fluorouracil. Gut Liver 2009;3:343-8. [PMID: 20431774 DOI: 10.5009/gnl.2009.3.4.343] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
19 Jang JW, Kay CS, You CR, Kim CW, Bae SH, Choi JY, Yoon SK, Han CW, Jung HS, Choi IB. Simultaneous Multitarget Irradiation Using Helical Tomotherapy for Advanced Hepatocellular Carcinoma With Multiple Extrahepatic Metastases. International Journal of Radiation Oncology*Biology*Physics 2009;74:412-8. [DOI: 10.1016/j.ijrobp.2008.08.034] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
20 Wang YL, Li MH, Cheng YS, Shi HB, Fan HL. Influential factors and formation of extrahepatic collateral artery in unresectable hepatocellular carcinoma. World J Gastroenterol 2005; 11(17): 2637-2642 [PMID: 15849825 DOI: 10.3748/wjg.v11.i17.2637] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
21 You CR, Jang JW, Kang SH, Bae SH, Choi JY, Yoon SK, Choi IB, Lee DH, Chun HJ, Choi BG. Efficacy of Transarterial Chemolipiodolization with or without 3-Dimensional Conformal Radiotherapy for Huge HCC with Portal Vein Tumor Thrombosis. Korean J Hepatol 2007;13:378. [DOI: 10.3350/kjhep.2007.13.3.378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
22 Jang JW, Bae SH, Choi JY, Oh HJ, Kim MS, Lee SY, Kim CW, Chang UI, Nam SW, Cha SB. A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management. Cancer Chemother Pharmacol. 2007;59:9-15. [PMID: 16614848 DOI: 10.1007/s00280-006-0239-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
23 Lim MSH, Ohtsuki T, Takenaka F, Kobayashi K, Akehi M, Uji H, Kobuchi H, Sasaki T, Ozeki E, Matsuura E. A Novel 89Zr-labeled DDS Device Utilizing Human IgG Variant (scFv): "Lactosome" Nanoparticle-Based Theranostics for PET Imaging and Targeted Therapy. Life (Basel) 2021;11:158. [PMID: 33670777 DOI: 10.3390/life11020158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Park HC, Seong J, Tanaka M, Zeng ZC, Lim HY, Guan S, Bae SH, Tak WY. Multidisciplinary management of nonresectable hepatocellular carcinoma. Oncology 2011;81 Suppl 1:134-40. [PMID: 22212947 DOI: 10.1159/000333276] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
25 Jang JW, You CR, Kim CW, Bae SH, Yoon SK, Yoo YK, Kim DG, Choi JY. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther. 2010;31:415-423. [PMID: 19821808 DOI: 10.1111/j.1365-2036.2009.04167.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 4.4] [Reference Citation Analysis]
26 Yang H, Woo HY, Lee SK, Han JW, Jang B, Nam HC, Lee HL, Lee SW, Song DS, Song MJ, Oh JS, Chun HJ, Jang JW, Lozada A, Bae SH, Choi JY, Yoon SK. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. Clin Mol Hepatol. 2017;23:128-137. [PMID: 28494528 DOI: 10.3350/cmh.2016.0071] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
27 Kim JS, Yoon SK, Kim JA, Kim CW, Bae SH, Choi JY, Jung CK. Long-term survival in a patient with ruptured hepatocellular carcinoma. Korean J Intern Med 2009;24:63-7. [PMID: 19270484 DOI: 10.3904/kjim.2009.24.1.63] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
28 Tsimberidou AM, Moulder S, Fu S, Wen S, Naing A, Bedikian AY, Daring S, Uehara C, Ng C, Wallace M, Camacho L, Kurzrock R. Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement. Cancer Chemother Pharmacol 2010;66:1087-93. [PMID: 20204368 DOI: 10.1007/s00280-010-1266-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]